Dapagliflozin is a selective SGLT2 inhibitor with established cardiovascular and renoprotective outcomes data, approved for type 2 diabetes, heart failure with reduced and preserved ejection fraction and chronic kidney disease. Simson Pharma's Dapagliflozin reference standard and impurities support the rigorous stability-indicating testing this high-priority cardiovascular-metabolic drug requires.
Simson Pharma Global Ltd. (UK) and Simson Pharma Global LLC (USA) supply high-quality Dapagliflozin Reference Standards, pharmacopoeial reference materials, and its related impurities to pharmaceutical manufacturers, CROs, analytical laboratories, universities, and regulatory organizations worldwide. To service the Europe and America market efficiently, Simson Pharma Limited has set up Simson Pharma Global Ltd. in United Kingdom and Simson Pharma Global LLC in USA respectively.